Brown Advisory Inc. Cuts Position in Kenvue Inc. $KVUE

Brown Advisory Inc. trimmed its position in shares of Kenvue Inc. (NYSE:KVUE) by 8.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,283,006 shares of the company’s stock after selling 114,055 shares during the period. Brown Advisory Inc. owned approximately 0.07% of Kenvue worth $26,853,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Amundi boosted its holdings in Kenvue by 82.5% during the 2nd quarter. Amundi now owns 14,509,890 shares of the company’s stock valued at $305,446,000 after acquiring an additional 6,559,261 shares during the period. Baird Financial Group Inc. lifted its position in shares of Kenvue by 10.6% during the second quarter. Baird Financial Group Inc. now owns 781,062 shares of the company’s stock worth $16,348,000 after purchasing an additional 75,088 shares in the last quarter. Guggenheim Capital LLC lifted its position in shares of Kenvue by 33.3% during the second quarter. Guggenheim Capital LLC now owns 255,061 shares of the company’s stock worth $5,338,000 after purchasing an additional 63,736 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Kenvue by 32.0% in the second quarter. EverSource Wealth Advisors LLC now owns 9,576 shares of the company’s stock valued at $200,000 after purchasing an additional 2,321 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Kenvue by 11.0% in the second quarter. Invesco Ltd. now owns 17,818,771 shares of the company’s stock valued at $372,947,000 after purchasing an additional 1,759,065 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.4%

NYSE:KVUE opened at $16.92 on Friday. The stock has a 50-day simple moving average of $16.09 and a 200-day simple moving average of $19.32. The stock has a market cap of $32.42 billion, a P/E ratio of 22.56 and a beta of 0.60. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last issued its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business’s quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the company earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.9%. The ex-dividend date was Wednesday, November 12th. Kenvue’s payout ratio is currently 110.67%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on KVUE. Edward Jones lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $22.50 to $22.00 in a research note on Friday, September 26th. Johnson Rice reissued a “neutral” rating on shares of Kenvue in a research note on Tuesday, October 28th. Rothschild Redb upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. Finally, UBS Group decreased their price objective on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $20.23.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.